Healthcare
Live Price
Offline$112.86
+1.27% today
1Y Change
+107.35%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Protagonist Therapeutics, Inc. (PTGX) is a Healthcare stock with a market cap of $6.28B and listed on NASDAQ. The stock last traded around $112.86 and up 107.3% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -89.4%, EPS growth of -145.9%, a dividend yield of 0.0%. What stands out right now is revenue -89.4%, EPS -145.9%, free cash flow -69.3% with operating margin -343.6% and ROIC -25.2%. Valuation already assumes a fairly strong business story at price/sales 136.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PTGX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PTGX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PTGX Max Drawdown
-16.38%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PTGX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$27.4M
+2.9% YoY
FY Net Income
-$125.6M
+1.4% YoY
Free Cash Flow
-$109.0M
-0.0% YoY
Revenue Growth
-89.4%
EPS Growth
-145.9%
Gross Margin
99.2%
Net Margin
-282.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 46M | 434M | 60M | 27M | 27M |
| Gross Profit | 45M | 434M | 60M | 27M | 27M |
| Operating Income | -158M | 253M | -94M | -131M | -126M |
| EBITDA | -128M | 254M | -90M | -128M | -123M |
| Net Income | -130M | 275M | -79M | -127M | -126M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 128M | 97M | 187M | 126M | 124M |
| Total Assets | 670M | 745M | 358M | 248M | 348M |
| Total Liabilities | 55M | 69M | 21M | 32M | 48M |
| Shareholder Equity | 615M | 675M | 337M | 216M | 300M |
| Total Debt | 10M | 11M | 1M | 4M | 6M |
| Net Debt | -118M | -86M | -186M | -122M | -118M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
108M
+0.3% YoY
Capital Expenditures
1M
-38.5% YoY
Free Cash Flow
109M
-0.0% YoY
Key ratios
Gross Margin
99.2%
Operating Margin
-343.6%
Net Margin
-282.8%
ROE
-19.9%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.